Physician profile
Sumit Mittle
NPI 1205852290
$17,327.38
in general payments reported to CMS, 2019-2025
42 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what 81% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,762 · 2020: $873 · 2021: $3,241 · 2022: $2,328 · 2023: $4,213 · 2024: $2,165 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,749 · Travel and Lodging: $1,375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,748.65 |
| Travel and Lodging | $1,374.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,754.66 | 2019-2024 | Xarelto |
| Cvrx, INC. | $2,685.90 | 2022-2025 | Barostim Neo System |
| Boston Scientific Corporation | $1,343.65 | 2019-2025 | Varithena Administration Pack, Watchman Access System, Watchman Flx |
| Abbott Laboratories | $1,084.57 | 2019-2025 | Aveir, Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $889.85 | 2020-2025 | Camzyos, Eliquis |
| Amgen INC. | $862.52 | 2019-2025 | Repatha, Repatha |
| Intra-Sana Laboratories | $765.73 | 2022-2024 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Merck Sharp & Dohme LLC | $751.81 | 2021-2025 | Verquvo |
| Medtronic Vascular, INC. | $720.72 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $620.22 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $603.78 | 2019-2025 | Farxiga |
| Pfizer INC. | $591.49 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $557.93 | 2019-2024 | Lifevest |
| Novo Nordisk INC | $516.55 | 2019-2025 | Rybelsus, Ozempic |
| Medtronic, INC. | $308.21 | 2021-2024 | Cobalt Dr Mri Surescan, Micra |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sumit Mittle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.